SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 25th, 2014 • RedHill Biopharma Ltd. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 31, 2013, is by and among RedHill Biopharma Ltd., a company limited by shares organized under the laws of the State of Israel (the “Company”), and Broadfin Healthcare Master Fund, LTD, a corporation formed under the laws of the State of the Cayman Islands (the “Buyer”).
AMENDMENT #2RedHill Biopharma Ltd. • February 25th, 2014 • Pharmaceutical preparations
BY AND BETWEEN: RedHill Biopharma Ltd., with principle place of business at 21 Ha’arba’a St. Tel-Aviv 64739, Israel (herein referred to as the “Client”),
THE SYMBOL "[****]" DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.RedHill Biopharma Ltd. • February 25th, 2014 • Pharmaceutical preparations
RedHill Biopharma Ltd. (“RedHill”) and IntelGenx Corp. (“IntelGenx”) have entered into that certain Co-Development and Commercialization Agreement (the “Agreement”), dated as of August 26th, 2010, in respect of the development of an oral film containing rizatriptan (“Product”). IntelGenx is the current sole and legal owner of New Drug Application #205394 (“NDA”) and Investigational New Drug #110753 (“IND”), both pertaining to the Product. RedHill and IntelGenx (collectively, the “Parties”) hereby enter into this Side Letter Agreement to define the Parties’ respective roles and responsibilities associated with the transfer and ownership of NDA #205394 and IND #110753 in respect of the Product.
ContractRedHill Biopharma Ltd. • February 25th, 2014 • Pharmaceutical preparations
THE SYMBOL “[****]” DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
Translation from Hebrew] FORM OF AGREEMENT Made and executed in Tel Aviv this 13 day of January 2014 BETWEENForm of Agreement • February 25th, 2014 • RedHill Biopharma Ltd. • Pharmaceutical preparations
WHEREAS: The Company is a public company as that term is defined in the Companies Law, 5759-1999 (hereinafter: “the Companies Law”), whose shares are listed for trading on the Tel Aviv Stock Exchange Ltd. (hereinafter: “the TASE”) and Nasdaq, and is engaged in medication development and purchase; and
